Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(63)

カスタマーフィードバック(12)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M3yzXWN6fG:2b4jpZ{BCe3OjeR?= M1jBfVExKG6P MYq3NkBp MmrVSG1UVw>? MX;Qc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= MVuyOFkxODh5Mx?=
HT-29 NGPGdoxEgXSxdH;4bYMhSXO|YYm= NUfQeYg1OTBibl2= NWnsO5kyPzJiaB?= M33lfGROW09? MYPQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? MXSyOFkxODh5Mx?=
HT-29 MmnyR5l1d3SxeHnjJGF{e2G7 M3P3eVExKG6P Mon4O|IhcA>? NIGwepRFVVOR NH3lT5BRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NH3MUnIzPDlyMEi3Ny=>
PC3 NV;t[5MxU2mwYYPlJGF{e2G7 M{PZZ|ExOCCwTR?= NUfTRndTOSCq MX;EUXNQ NEXUc49Rd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> Mlz1NlE6Pzh4OEO=
PC3 MY\LbY5ie2ViQYPzZZk> MWexNFAhdk1? M{XDblEhcA>? NGXNU4NFVVOR Mkj5SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NGL1fnQzOTl5OE[4Ny=>
PC3 NVP2fIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CwfVEvPSEQvF2= MYCxJIg> NWjjZ4R2TE2VTx?= M1TxVmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= M37z[FIyQTd6Nkiz
HEK293 MoGxSpVv[3Srb36gRZN{[Xl? M33NSlExOCCwTR?= M{LMdFghcA>? M1XVTGROW09? MY\Jcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? M{DOZ|IyPTN7M{Cx
BT-20 MVXLbY5ie2ViQYPzZZk> NVTpe49TOjBizszN NHW1bYtFVVOR MVXEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? NXK3WJhROjF|NUO1OVE>
U937 NGX2NoxCdnSrYnHjeIVzcWGuIFHzd4F6 M1zxXlUxKM7:TR?= NHXmVIE1QCCq Mn71SG1UVw>? MmDMTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| MkLiNlEyPDJzME[=
U937 M{L6bmFvfGmkYXP0[ZJq[WxiQYPzZZk> MYW1NEDPxE1? NYfBZppvPDhiaB?= NYHjVIVCTE2VTx?= NFLmNXpFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| M2rC[|IyOTR{MUC2
U937 NGWzUHZCdnSrYnHjeIVzcWGuIFHzd4F6 Mn7QOVAh|ryP MUG0PEBp MoPXSG1UVw>? MUDEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> MVqyNVE1OjFyNh?=
MCF-7 MWDBeZRweGijZ4mgRZN{[Xl? NWD3RnhjOzBibl2= M3voWVQhcA>? NWLIVWI{TE2VTx?= M3:wT2lv\HWlZYOgZZV1d3CqYXf5 Ml7wNlAxOjhzM{S=
U87MG MWHLbY5ie2ViQYPzZZk> NYjkSFI{OSEQvF2= MnP2OkBp M{jP[GROW09? NGTQcZdRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= MoPzNVk5PDh2MES=
U87MG NUnlUlhpU2mwYYPlJGF{e2G7 MXuxJO69VQ>? MkLKOkBp NHPhTmRFVVOR M1fTV3BwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u NY[0e41NOTl6NEi0NFQ>
U87MG M3\WbWtqdmG|ZTDBd5NigQ>? MojQNUDPxE1? NWO3ZYhoPiCq M{fpOWROW09? MUHEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NGjGcZUyQTh2OESwOC=>
U87MG M2L2T2tqdmG|ZTDBd5NigQ>? NUfE[2NOOSEQvF2= NGj6NHg3KGh? MUPEUXNQ MWrEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NUnmc3VVOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb Mk\wRZV1d3CqYXf5JGF{e2G7 NW\ne3ZxOC5{IN88US=> MVSyOEBp M2nqSWROW09? M{e0Vmlv\HWlZYOgZZV1d3CqYXf5 MVKxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 MnPlRZV1d3CqYXf5JGF{e2G7 MUOwMlIh|ryP Mo\jNlQhcA>? NYDnZ3ozTE2VTx?= MlfDTY5lfWOnczDheZRweGijZ4m= MoTqNVg{QTF7NEm=
H4 NI\Z[phHfW6ldHnvckBCe3OjeR?= NVjjNXJVOC5{IN88US=> NXqyWlZIOjRiaB?= MkfZSG1UVw>? MnXNTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> MnzzNVgxOjR3OES=
HeLa MknySpVv[3Srb36gRZN{[Xl? NY\W[mtFOTByIH7N NEHxVGc{PiCq NX;rNYc5TE2VTx?= NGD5cllKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MkHENVc2PjN|OEW=
HeLa Mlj5SpVv[3Srb36gRZN{[Xl? MojuNVAxKG6P NYrldZo4OzZiaB?= M1\MUWROW09? M{\ZZmlv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NF:xfIwyPzV4M{O4OS=>
HeLa M2XUUWZ2dmO2aX;uJGF{e2G7 MYOxNFAhdk1? MX[zOkBp NV3qTIFbTE2VTx?= NX[0emFvUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NYnmd4toOTd3NkOzPFU>
SYF MVrGeY5kfGmxbjDBd5NigQ>? M3PKc|ExOCCwTR?= MmPENlQhcA>? MXzEUXNQ NXS2bIVRUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NIPwd5MyPzV4M{O4OS=>
SYF Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvwPJQyODBibl2= NXiwbVRqOjRiaB?= MYLEUXNQ MX;JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| M{D0Z|E4PTZ|M{i1
HEK293T M2TyRmFvfGm4aYLhcEBCe3OjeR?= NUHPW5RMOSCwTR?= NUDERYRGPCCm M1zOVWROW09? MV;JcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= M4XXSFE4PDh3NUCx
HEK293T NIf2WXBCdnSrdnnyZYwhSXO|YYm= NEnwem0yKG6P M122S|Qh\A>? NF;vXo5FVVOR MWjJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NXPjWo5[OTd2OEW1NFE>
PBMC MVHGeY5kfGmxbjDBd5NigQ>? MXWxJI5O NULOcIROOTRiZB?= MWjEUXNQ NWXrT3J[WmWmdXPld{BES1J3IHTlcpNqfHl? MluxNVc1QDV3MEG=
PBMC M3jhbGZ2dmO2aX;uJGF{e2G7 NF74XGYyKG6P NGLjTZcyPCCm M1HmXWROW09? MlHjSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> MUixO|Q5PTVyMR?=
HEK293 cells M3XtWmtqdmG|ZTDBd5NigQ>? NWnzZ4UxPTBibl2= MWS0OUBucW5? MXnEUXNQ NFqy[mtKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P MoD3NVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NF35XYVHfW6ldHnvckBCe3OjeR?= NWLPfJYzOTByIH7N NXP6[2ZiPCCq MYnEUXNQ MW\JcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> MXKxO|EzQDJ4Mh?=
Human mixed lymphocyte NX7GOWZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPGWFc2KG6P NWLYUFBbTE2VTx?= M2\p[2lEPTB;MT62JI5ONg>? MVSxOlE5PTh4NR?=
Lewis rat lymph node cells MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi1JO69VQ>? MUjEUXNQ Mom4TWM2OD1{Lk[g{txO M17QfFE3OTh3OE[1
cells from the thymus of normal BALB/c mice NFjFU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTwNVAhdk1? M{TuPVczKGh? MXPEUXNQ MVTJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P M4ntUVExODJzOUS4
MRK-nu-1 M{TxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwOES1JJBO MluyV2FPT0WU
OCUB-M M4XKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\2[YJHUUN3ME21MlI1KHCP NHy3dVJUSU6JRWK=
SF539 NWS3WpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjzTWM2OD1zMT62JJBO MVzTRW5ITVJ?
ES4 NHnTV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[0TWM2OD1{MT61JJBO Mln5V2FPT0WU
RL95-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFyNzDwUS=> NH[z[5NUSU6JRWK=
LC-2-ad NFfnUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR{MzDwUS=> MUTTRW5ITVJ?
Daudi MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYro[lVIUUN3ME20N|QheE1? NF3Gd2xUSU6JRWK=
NTERA-S-cl-D1 NVLkSnFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTR2MzDwUS=> NXq1dpRnW0GQR1XS
OS-RC-2 M3fYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPnU4lKSzVyPU[1NkBxVQ>? NHfqUXJUSU6JRWK=
VA-ES-BJ M4nIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDINHBKSzVyPUeyN{BxVQ>? M3flOXNCVkeHUh?=
GR-ST MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKwTWM2OD16NE[gdG0> MmLBV2FPT0WU
SW872 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S0d2lEPTB;OES2JJBO NGDF[YxUSU6JRWK=
NOS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXyXm5KSzVyPUi3NUBxVQ>? MXTTRW5ITVJ?
MC116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTl6NTDwUS=> MYfTRW5ITVJ?
NCI-H1355 M121bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f3[2lEPTB;MT6wNUBvVQ>? MYHTRW5ITVJ?
RPMI-8226 NIL4fYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjkNWdKUUN3ME2xMlE6KG6P MkGyV2FPT0WU
TE-15 NGXN[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwM{[gcm0> MkfGV2FPT0WU
Ramos-2G6-4C10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HvOGlEPTB;MT60OkBvVQ>? NWnyW3pIW0GQR1XS
KU812 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDDTWM2OD1{LkCxJI5O M3r2TnNCVkeHUh?=
EW-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELDUJhKSzVyPUKuNVchdk1? NIDrbZdUSU6JRWK=
KS-1 NVH3cIJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTtTWM2OD1{LkS1JI5O NYHi[pJIW0GQR1XS
SK-LMS-1 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvnR41kUUN3ME2yMlQ6KG6P NIXKe2ZUSU6JRWK=
TGBC1TKB Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJwNkmgcm0> MWDTRW5ITVJ?
TE-6 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXyS4dJUUN3ME2yMlc4KG6P NXyzfIpEW0GQR1XS
ETK-1 NYruTJZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LrOGlEPTB;Mj64NkBvVQ>? M4THdXNCVkeHUh?=
BE-13 M1O1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwOUmgcm0> MonlV2FPT0WU
A3-KAW MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTEUZZKSzVyPUKuPVkhdk1? NXvOO49rW0GQR1XS
TE-10 NHnyUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTWTWM2OD1|LkOgcm0> M4\ZRnNCVkeHUh?=
DOHH-2 MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXQUYF{UUN3ME2zMlM2KG6P NETMW|FUSU6JRWK=
ES6 NY\nT|JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP5O4JKSzVyPUOuOFMhdk1? M4TSRXNCVkeHUh?=
OPM-2 M1;xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlmzTWM2OD12LkG1JI5O MkTJV2FPT0WU
SH-4 M2q1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwM{Sgcm0> M3LIWHNCVkeHUh?=
NB13 NYPHNJN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHryVoFKSzVyPUSuN|Yhdk1? MX\TRW5ITVJ?
HUTU-80 NVzjTVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHBT5pKSzVyPUSuOFIhdk1? M1TBbHNCVkeHUh?=
CCRF-CEM NFfrOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRwOUSgcm0> NGrFUlJUSU6JRWK=
TGBC24TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTVwNUGgcm0> NGXXUndUSU6JRWK=
697 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfPbYRKSzVyPU[uNlghdk1? MnXqV2FPT0WU
J-RT3-T3-5 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojpTWM2OD14LkS2JI5O NH7nTY9USU6JRWK=
KALS-1 NFfuVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLaVVZKSzVyPU[uOVYhdk1? NGnZe2VUSU6JRWK=
no-10 M1nSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW5TWM2OD15LkK5JI5O MmfnV2FPT0WU
SK-NEP-1 M2\XdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRThwN{mgcm0> NWTNXmdpW0GQR1XS
L-540 NISzTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKyTWM2OD1zMD60NkBvVQ>? NIG1fGhUSU6JRWK=
JiyoyeP-2003 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3vU2lKSzVyPUGwMlk1KG6P MV3TRW5ITVJ?
HH NXf4ZYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\pPYtKSzVyPUGxMlM6KG6P MVHTRW5ITVJ?
SR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXz[JVKSzVyPUGxMlQ2KG6P NIG0S|lUSU6JRWK=
QIMR-WIL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PJN2lEPTB;MUGuPFUhdk1? MX3TRW5ITVJ?
A4-Fuk NVTqeodrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrDV5JKSzVyPUGzMlEzKG6P MknUV2FPT0WU
CESS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;4OmlEPTB;MUOuNVMhdk1? Mn2wV2FPT0WU
KE-37 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF4LkC3JI5O NXHTd|BCW0GQR1XS
SK-UT-1 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF4LkixJI5O MlzGV2FPT0WU
SIG-M5 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTMcpNKUUN3ME2xO{4zPSCwTR?= NXvKO3NoW0GQR1XS
HT M3XLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTOWXBKSzVyPUG3MlYhdk1? MVzTRW5ITVJ?
DEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF5Lkm5JI5O MoPaV2FPT0WU
SK-PN-DW MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;jT2VKSzVyPUKwMlI{KG6P NEDFNXhUSU6JRWK=
RPMI-8402 M2j0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m3PGlEPTB;MkGuO|chdk1? MXfTRW5ITVJ?
RPMI-6666 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;KTI9KSzVyPUK0MlQzKG6P M3rOXXNCVkeHUh?=
NCI-H720 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi5bFhkUUN3ME2yOU41OSCwTR?= MWHTRW5ITVJ?
EW-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml70TWM2OD1{Nj64O{BvVQ>? MlPqV2FPT0WU
BL-70 M4n3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ6LkO4JI5O MYnTRW5ITVJ?
SF126 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\2eZFKSzVyPUOwMlM5KG6P NIH1Z2dUSU6JRWK=
BC-1 M1XFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j6OmlEPTB;M{GuNlYhdk1? NUn5d2dsW0GQR1XS
MHH-PREB-1 MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN{LkS0JI5O MUjTRW5ITVJ?
A101D MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGwWYJKSzVyPUOyMlYzKG6P MYDTRW5ITVJ?
NMC-G1 NFjueG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jNXmlEPTB;M{OuOlchdk1? NUHEUHhCW0GQR1XS
LB1047-RCC NXe5[FYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTN2Lk[5JI5O M2jnWXNCVkeHUh?=
EM-2 M2DPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\nb3h[UUN3ME2zPE42OyCwTR?= MXTTRW5ITVJ?
COLO-684 NFrsTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnVTWM2OD1|OT64JI5O NUfTZWxwW0GQR1XS
Becker NW\L[XZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCSmlEPTB;NEGuNFUhdk1? NUHEbW15W0GQR1XS
BL-41 M4PkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;GTWM2OD12Mz62OkBvVQ>? MkniV2FPT0WU
MDA-MB-134-VI MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH72fZFKSzVyPUS0MlAzKG6P MUPTRW5ITVJ?
L-363 NGXwTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\1TWM2OD12ND63N{BvVQ>? NGi4eZFUSU6JRWK=
ECC4 NGPNRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTR2Lke4JI5O M4DUOHNCVkeHUh?=
A388 NWLFVWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfhTWM2OD12ND64NkBvVQ>? MVLTRW5ITVJ?
HEL MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfFXXNKSzVyPUS5Mlc6KG6P MljsV2FPT0WU
RKO M1:0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVyLkK5JI5O NX7SNHFqW0GQR1XS
KINGS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjsd2VKSzVyPUWxMlU2KG6P NHjyfHBUSU6JRWK=
EB-3 NUnnW|g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2yPVJKSzVyPUWyMlY4KG6P MWDTRW5ITVJ?
ARH-77 M3WzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTV{Lkigcm0> NXvFbGVKW0GQR1XS
GCIY NFjpZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXpR5RKSzVyPUWzMlQ3KG6P M3jWdHNCVkeHUh?=
NCI-H1304 NYXrXHhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrDXWNKSzVyPUW3MlIzKG6P NH;peZlUSU6JRWK=
KARPAS-299 NE\nU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInWe2lKSzVyPU[xMlgzKG6P M1jjVnNCVkeHUh?=
IA-LM MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWwcnZXUUN3ME22PE4yOyCwTR?= MWrTRW5ITVJ?
GI-1 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL3PGtKSzVyPUewMlM6KG6P NELxZ3BUSU6JRWK=
TE-11 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTVTWM2OD15Nz6xO{BvVQ>? NWizZ3RPW0GQR1XS
LS-411N NHzWUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK0XJlKSzVyPUe3MlU4KG6P NHHpUIVUSU6JRWK=
no-11 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj4b45KSzVyPUizMlI1KG6P MYrTRW5ITVJ?
MV-4-11 NX;tU2t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\FU2pKSzVyPUizMlc{KG6P MoXCV2FPT0WU
BV-173 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHtW2VvUUN3ME24N{46PyCwTR?= NHfsZoFUSU6JRWK=
CMK MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLmTWM2OD16ND6xOkBvVQ>? M1X6NXNCVkeHUh?=
LC4-1 M{HIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nMW2lEPTB;OE[uO|Ihdk1? MmrBV2FPT0WU
COR-L279 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXBc3JKSzVyPUi3MlI2KG6P MmHUV2FPT0WU
NCI-H209 NVzVVJViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jH[2lEPTB;OEeuOFEhdk1? MXvTRW5ITVJ?
Raji MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnoOHczUUN3ME24PU44OiCwTR?= NXq2WFRsW0GQR1XS
LB996-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTl|LkSzJI5O MoLMV2FPT0WU
NCI-H526 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnQNJA3UUN3ME25N{42QSCwTR?= M2LCcHNCVkeHUh?=
KGN NVrJVVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[wZ2lEPTB;OU[uNlkhdk1? NXvkd|VXW0GQR1XS
MOLT-4 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP6VYs1UUN3ME25Ok44QSCwTR?= M3ywT3NCVkeHUh?=
PF-382 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT2epVKSzVyPUm2Mlc6KG6P NILrRW1USU6JRWK=
BC-3 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED5dYhKSzVyPUm5MlE5KG6P MmDKV2FPT0WU
KARPAS-422 NUTYdYpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfuS3FiUUN3ME2xNFIvODlibl2= NIn5boRUSU6JRWK=
SBC-1 M1\qc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DwNGlEPTB;MUC3Mlc2KG6P MnTBV2FPT0WU
LC-1F M{HUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTucFdFUUN3ME2xNFgvODVibl2= M1vLV3NCVkeHUh?=
GB-1 NH3VOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTEboJKSzVyPUGwPU4xOiCwTR?= MV3TRW5ITVJ?
SNB75 M4nkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFzOT62PUBvVQ>? NVzNeFN2W0GQR1XS
BB65-RCC MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPCRW5KSzVyPUGxPU46OyCwTR?= NX7ac2dkW0GQR1XS
NCI-N87 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvyfY9KSzVyPUGyNU46QCCwTR?= NVf5cXR[W0GQR1XS
IST-MEL1 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF{Mj6zPEBvVQ>? MXnTRW5ITVJ?
HOP-62 NE[3UZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\lTWM2OD1zMk[uPFkhdk1? M{DQV3NCVkeHUh?=
ACN NWf2VGZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfIc494UUN3ME2xOFYvPzVibl2= M3PvVHNCVkeHUh?=
DMS-114 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF3MD62O{BvVQ>? NGDqcYxUSU6JRWK=
MLMA MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSxTWM2OD1zNUmuPFghdk1? MmS4V2FPT0WU
HT-144 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TIPGlEPTB;MU[1MlQ{KG6P NVLuXpIzW0GQR1XS
C2BBe1 M1rPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTQTWM2OD1zNkeuO|Yhdk1? NXTa[|dyW0GQR1XS
L-428 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj3TWM2OD1zN{euO{BvVQ>? NH\pZ3ZUSU6JRWK=
DU-4475 NEDVSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv4WoFiUUN3ME2xPFcvPjhibl2= M{XufHNCVkeHUh?=
CP67-MEL NFfBPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[x[I5KSzVyPUG5PU4{QCCwTR?= M2LPWHNCVkeHUh?=
MEG-01 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfETZZKSzVyPUKwNU46PiCwTR?= MnPOV2FPT0WU
IST-SL2 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7pTWM2OD1{MEiuOlMhdk1? MYnTRW5ITVJ?
ES8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULZd45kUUN3ME2yNlUvQTRibl2= M3\VeXNCVkeHUh?=
COLO-800 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HYd2lEPTB;MkO1MlI5KG6P M3r0eXNCVkeHUh?=
MFH-ino M1[5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjlVVFCUUN3ME2yN|UvQDRibl2= NFjHfJZUSU6JRWK=
OVCAR-4 NXe4TI9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnZTWM2OD1{M{euNlQhdk1? NHL6S3pUSU6JRWK=
PSN1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfCTWM2OD1{NEKuO|Ehdk1? NFSxeVVUSU6JRWK=
EW-12 NV3zdVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\zPWNKSzVyPUK0N{4yKG6P NEnac5JUSU6JRWK=
HCC1599 M4jEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ4MT60O{BvVQ>? NVj6bG1pW0GQR1XS
SJSA-1 M{XJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DzRWlEPTB;MkexMlQ3KG6P NGLaOGNUSU6JRWK=
ST486 M2rRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknnTWM2OD1{OU[uNVQhdk1? M{K5eHNCVkeHUh?=
NOMO-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHaTWM2OD1|MECuNlEhdk1? NUTTblNzW0GQR1XS
MN-60 M3TMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnEN2tqUUN3ME2zNFUvOzJibl2= NVzHVHRsW0GQR1XS
HCC1187 NWPiWFhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\lTWM2OD1|MEeuNlUhdk1? NVv2fmJTW0GQR1XS
SW982 M{Kz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;RUGlEPTB;M{G0Mlc2KG6P MWHTRW5ITVJ?
LB647-SCLC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TzRmlEPTB;M{K4MlcyKG6P MmfOV2FPT0WU
HC-1 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr4R25KSzVyPUOzOU42KG6P M3jKR3NCVkeHUh?=
EHEB NFLqR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKz[oVYUUN3ME2zN|cvPTJibl2= Ml:wV2FPT0WU
TUR NYDI[po4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3BdoZWUUN3ME2zOlMvQTVibl2= MWnTRW5ITVJ?
LU-139 M2LZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPPe4NKSzVyPUO3PE4xOiCwTR?= NIPu[|VUSU6JRWK=
NB1 M{jpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPHTWM2OD1|OESuOFUhdk1? MX3TRW5ITVJ?
BB30-HNC M4T5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfoWJJKSzVyPUO4PE4{OiCwTR?= MVfTRW5ITVJ?
HAL-01 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLtdJVTUUN3ME2zPFkvOjZibl2= MY\TRW5ITVJ?
K5 M1XzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXrTWM2OD12MUGuN|chdk1? NXTocFZmW0GQR1XS
MZ2-MEL NEf6OopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTl[GJkUUN3ME20NVMvPjRibl2= MXTTRW5ITVJ?
RXF393 M4q2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm2TWM2OD12MU[uOFUhdk1? NXv4bIxRW0GQR1XS
NCI-H1648 NFrM[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2qweGlEPTB;NEG3MlU{KG6P NH3RNFRUSU6JRWK=
TE-12 M1jSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;GWWVFUUN3ME20N|QvOjZibl2= Mkn0V2FPT0WU
EoL-1- M4WwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fqTmlEPTB;NEO3Mlk5KG6P MkGzV2FPT0WU
JAR Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPBT5VKSzVyPUSzPE43OiCwTR?= MU\TRW5ITVJ?
DSH1 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HPd2lEPTB;NEW4MlkyKG6P NX;Ke3JmW0GQR1XS
NCI-H187 NVzrNnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTUTWM2OD12NkKuPFEhdk1? NWjYN3ZxW0GQR1XS
HCE-4 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR5Nz62OkBvVQ>? NH3FVWRUSU6JRWK=
8-MG-BA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XZSGlEPTB;NUixMlUzKG6P NWTIVWZHW0GQR1XS
KLE NFnOVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPNW4JKSzVyPUW4OU4zKG6P M1n0XXNCVkeHUh?=
KNS-42 NGnFNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3J[YM3UUN3ME21PFYvQDFibl2= M{L5W3NCVkeHUh?=
MSTO-211H M{\1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXYW|BKSzVyPU[wPU44PCCwTR?= NYTwcnIyW0GQR1XS
GDM-1 NI\zdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZzND6wPUBvVQ>? M{LaUXNCVkeHUh?=
TE-1 M2K4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL2flJKSzVyPU[0Ok4yOiCwTR?= MXLTRW5ITVJ?
BT-474 M{TNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTZ2Nz6wOkBvVQ>? M33S[XNCVkeHUh?=
KARPAS-45 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX5ZXFOUUN3ME22OFcvPiCwTR?= NYS0[|BbW0GQR1XS
MOLT-16 MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTZ2Nz65N{BvVQ>? NWPsPXVPW0GQR1XS
KURAMOCHI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[yTWM2OD14NUeuOVEhdk1? NW\BXXdiW0GQR1XS
K-562 M3jjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn6S4dRUUN3ME22OlkvPTFibl2= MnH2V2FPT0WU
EKVX MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZ5Mj63NUBvVQ>? MWLTRW5ITVJ?
GAK NHjCRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jiNmlEPTB;Nke1MlMhdk1? Mn35V2FPT0WU
NCI-SNU-5 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO5TWM2OD14OUCuNFEhdk1? MmO5V2FPT0WU
NCI-H2126 NHPQfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTd{Nj64O{BvVQ>? MXPTRW5ITVJ?
CTV-1 NFTVW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrESmw4UUN3ME23OFQvQSCwTR?= MUDTRW5ITVJ?
SW962 M4TldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3LTWM2OD15NEiuOFQhdk1? NVrm[o0yW0GQR1XS
MONO-MAC-6 NF;xXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTaTWM2OD15NU[uPVMhdk1? NXrK[3lGW0GQR1XS
NCI-H748 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTd3OD65PUBvVQ>? M363enNCVkeHUh?=
NCI-H524 NF7rfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHkTWM2OD15OECuO|Mhdk1? NVXRNo5WW0GQR1XS
LS-123 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\NT2lEPTB;N{m1MlY6KG6P MWjTRW5ITVJ?
NB7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWxVpBKSzVyPUixOE4yPCCwTR?= NEHWPWdUSU6JRWK=
LS-1034 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTh{OD65PEBvVQ>? NF\WXHJUSU6JRWK=
TE-5 NWm2O5M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\QU5pKSzVyPUi4N{42PiCwTR?= MVjTRW5ITVJ?
A704 M1zEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli2TWM2OD16OUmuNVUhdk1? MmP2V2FPT0WU
TK10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTlzNj6wN{BvVQ>? M3rtT3NCVkeHUh?=
NCI-H345 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTl2Mz6yNkBvVQ>? MXjTRW5ITVJ?
CGTH-W-1 NIXFflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjsTWM2OD17NEiuNVMhdk1? MUjTRW5ITVJ?
NCI-H510A MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnFTWM2OD17OEWuNVIhdk1? M373e3NCVkeHUh?=
NCI-H1963 M2DKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;SXJM2UUN3ME2xMlA{Ojl{IN88US=> M3HTVXNCVkeHUh?=
SCC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwMEO0NVQh|ryP NVP4fYtwW0GQR1XS
EW-11 M4LLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwMEi3OFMh|ryP M3Pie3NCVkeHUh?=
CPC-N MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwMEi4JO69VQ>? NXX3UVVpW0GQR1XS
NCI-H1417 NEe4dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HScmlEPTB;MT6xNlI3KM7:TR?= MVTTRW5ITVJ?
DG-75 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfNe|V3UUN3ME2xMlE3Ojh3IN88US=> NI\0Um1USU6JRWK=
HD-MY-Z M2PaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn5TWM2OD1zLkG2OFE3KM7:TR?= MV\TRW5ITVJ?
ATN-1 M{HaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknuTWM2OD1zLkK2NlA6KM7:TR?= NXXyfpJ[W0GQR1XS
KM-H2 NVzZUm04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwMk[0NFgh|ryP NXK3c3RJW0GQR1XS
NCI-H2081 M2DpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTj[HJKSzVyPUGuNlY3OzdizszN MUjTRW5ITVJ?
HL-60 M2fXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwMk[5OVkh|ryP M4rjN3NCVkeHUh?=
DB NYHsOHhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwMkeyOFIh|ryP MULTRW5ITVJ?
NCI-H1522 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XJ[mlEPTB;MT6yPFg5PyEQvF2= Mk\oV2FPT0WU
AM-38 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Wwe2lEPTB;MT6zNFczKM7:TR?= M{\4TnNCVkeHUh?=
NCI-H446 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjzPXJKSzVyPUGuN|IyOjFizszN MXzTRW5ITVJ?
SU-DHL-1 M3rDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwM{K4NFEh|ryP M{nxTnNCVkeHUh?=
NH-12 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwM{[zO|Qh|ryP MYLTRW5ITVJ?
DMS-79 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPKTWM2OD1zLkO2PFY3KM7:TR?= MXHTRW5ITVJ?
NCI-H716 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwM{i5PFYh|ryP NHLwT4JUSU6JRWK=
ML-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\YVYFlUUN3ME2xMlQyPTJ7IN88US=> M2LrUHNCVkeHUh?=
NB10 M4jI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO5[mtwUUN3ME2xMlQ3PjN{IN88US=> NUPk[lFsW0GQR1XS
ONS-76 M4e4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvYSVNKSzVyPUGuOVM2PjlizszN M1zId3NCVkeHUh?=
LOUCY MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37KZmlEPTB;MT61OFY2PyEQvF2= Mn;nV2FPT0WU
SCLC-21H MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;SWplKSzVyPUGuOVg2QDJizszN M1v0VXNCVkeHUh?=
TGW MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTRbYlKSzVyPUGuOlM6PzVizszN MXTTRW5ITVJ?
LXF-289 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVziVFl{UUN3ME2xMlc{OjZ6IN88US=> M132UHNCVkeHUh?=
BB49-HNC MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT4dXY2UUN3ME2xMlc{PTh4IN88US=> NYfoTWFCW0GQR1XS
NCI-H747 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHlTmJtUUN3ME2xMlc2OzR4IN88US=> MlfyV2FPT0WU
LU-165 NFj4fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XSSGlEPTB;MT64OFk5PiEQvF2= MUHTRW5ITVJ?
OMC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwOUWwOlYh|ryP NGHqU3RUSU6JRWK=
RCC10RGB NEjw[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT6TWM2OD1zLkm1PFE4KM7:TR?= NGraRWNUSU6JRWK=
SW684 NVPMbFVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDaTWM2OD1zLkm2NFk6KM7:TR?= MkPCV2FPT0WU
TE-8 M3O2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTCTWM2OD1{LkC1OVU6KM7:TR?= NHLielJUSU6JRWK=
SK-N-DZ NITUcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iycGlEPTB;Mj6xN|I4PCEQvF2= MlexV2FPT0WU
EVSA-T NYfPPVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzxO29KSzVyPUKuNVc{OTVizszN Ml7SV2FPT0WU
KASUMI-1 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn2T2hsUUN3ME2yMlE5QDF3IN88US=> M{PLZXNCVkeHUh?=
NKM-1 NIfvR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHpUGUzUUN3ME2yMlI2PDd{IN88US=> MXvTRW5ITVJ?
CAL-148 NHfXfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJwM{O2NVQh|ryP NInkfoxUSU6JRWK=
NCI-H64 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXqTWM2OD1{LkO0NlMzKM7:TR?= MX\TRW5ITVJ?
KNS-81-FD NVi4VJFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[4WmlEPTB;Mj6zOlYzKM7:TR?= MmrUV2FPT0WU
KM12 M2K2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTYPJBKSzVyPUKuOFA5OzlizszN NUD3VmVEW0GQR1XS
SW954 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXYTWM2OD1{LkS3O|c6KM7:TR?= Mn\nV2FPT0WU
NCI-H1395 Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfpV|BKSzVyPUKuOVI3PDVizszN MX\TRW5ITVJ?
DJM-1 NGHsVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwNkC2N{DPxE1? MnTtV2FPT0WU
COLO-668 NGnrUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T2OGlEPTB;Mj64NlY6PSEQvF2= M4P5VHNCVkeHUh?=
NCI-H1436 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwOEW2NVUh|ryP M33wWXNCVkeHUh?=
LB2241-RCC NH\KUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K5XmlEPTB;Mj64Olg{QSEQvF2= M3X2bHNCVkeHUh?=
GT3TKB NELORo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm0XFBKSzVyPUKuPFkxPTVizszN NF;1UJZUSU6JRWK=
COLO-824 NX\0eYdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjCTWxNUUN3ME2yMlg6PzZ6IN88US=> NYTvb|hOW0GQR1XS
ES1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fyfGlEPTB;Mj64PVg4QSEQvF2= NHS2WXBUSU6JRWK=
LB771-HNC NGPBOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHtTWM2OD1{LkmwPVQ3KM7:TR?= NGjSbHVUSU6JRWK=
GI-ME-N M{TY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;hU5pKSzVyPUOuNFA6ODRizszN MmfsV2FPT0WU
NALM-6 MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD6dGJ4UUN3ME2zMlAxQTN|IN88US=> MnTYV2FPT0WU
LU-134-A M3\lbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL4TYkyUUN3ME2zMlA2PDJ3IN88US=> M1jYZ3NCVkeHUh?=
DMS-153 NV;iTlNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;Ueo1KSzVyPUOuNFU5OjRizszN M374bXNCVkeHUh?=
MZ1-PC NGrZTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\5PJhUUUN3ME2zMlA6ODd6IN88US=> NF7oN4dUSU6JRWK=
NCI-H1155 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXkU4pKSzVyPUOuNVE3OSEQvF2= MYPTRW5ITVJ?
CAS-1 NI\uVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwMUO3NFch|ryP NVnUNW5[W0GQR1XS
D-502MG NXi2UXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwMUSzPUDPxE1? M4rnTHNCVkeHUh?=
NCI-H2141 NXrvU5NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNwMUe0OVIh|ryP M1XISXNCVkeHUh?=
NB6 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrnS3pKSzVyPUOuNVgzPTlizszN MWHTRW5ITVJ?
NCCIT NV3oPJI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTNwMkG4NFkh|ryP M4XPcHNCVkeHUh?=
NB69 M1PEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL5e5VKSzVyPUOuN|E5QTFizszN MmLTV2FPT0WU
JVM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNwM{[0N|Mh|ryP MlzDV2FPT0WU
K052 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi0WWMyUUN3ME2zMlM4QTZ6IN88US=> NE\icodUSU6JRWK=
HCC2157 M2jEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSyVHI3UUN3ME2zMlU{OjJ6IN88US=> M4fzO3NCVkeHUh?=
KMOE-2 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;sdlFKSzVyPUOuOVQzPDJizszN NHzsfVJUSU6JRWK=
SF268 NVPqRVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTKUVdKSzVyPUOuO|E2PTRizszN MmDUV2FPT0WU
CHP-126 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwN{[0OVgh|ryP M4S5XHNCVkeHUh?=
CP66-MEL Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfTbotoUUN3ME2zMlc6ODl2IN88US=> NX\0WJdrW0GQR1XS
NCI-H69 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[5e2lEPTB;ND6wNVk{PiEQvF2= NULqbGdMW0GQR1XS
A253 NGfjTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP5TWM2OD12LkCyNVAyKM7:TR?= MkfzV2FPT0WU
NB14 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPHTWM2OD12LkGwOFc6KM7:TR?= M2XOeHNCVkeHUh?=
NCI-H1694 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwMUOxNVIh|ryP MX;TRW5ITVJ?
NCI-H2196 NGP1ZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\Kc5pKSzVyPUSuNVcyPjlizszN NWXzcmFmW0GQR1XS
TE-9 NGfkcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XhXmlEPTB;ND6xO|U5OiEQvF2= NEfpZodUSU6JRWK=
D-283MED NFKzTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\hO25KSzVyPUSuNVg5PCEQvF2= MWLTRW5ITVJ?
OCI-AML2 NFTWW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHlTWM2OD12LkG5OFg6KM7:TR?= M3zlbXNCVkeHUh?=
D-263MG MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjUVnExUUN3ME20MlIzQTZzIN88US=> MXLTRW5ITVJ?
MPP-89 MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnhV5ZpUUN3ME20MlI4OzB2IN88US=> MUTTRW5ITVJ?
LAMA-84 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwM{C0NlEh|ryP NYnjc4I5W0GQR1XS
LB373-MEL-D MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvXXY5VUUN3ME20MlM3Pzh7IN88US=> NWjCfmt1W0GQR1XS
UACC-257 M4jXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rP[mlEPTB;ND6zPVU{PCEQvF2= NHzMR3RUSU6JRWK=
MC-CAR NV\heWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwNEO5PUDPxE1? NEi4SolUSU6JRWK=
COLO-320-HSR NWfpbY52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;hTWM2OD12LkS0OFI4KM7:TR?= NWn5PGNWW0GQR1XS
P30-OHK M2jOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULW[VFVUUN3ME20MlY3PThzIN88US=> NGO0b4JUSU6JRWK=
UACC-812 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjqb|lKSzVyPUSuOlkyPjFizszN NY\QZpdiW0GQR1XS
CTB-1 NID1PVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfmTYtKSzVyPUSuO|E2PTVizszN MUfTRW5ITVJ?
ALL-PO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRwOESwO|ch|ryP NUHnd2dSW0GQR1XS
SK-MEL-2 M3fVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH4VnJKSzVyPUSuPFY6PTVizszN MU\TRW5ITVJ?
TC-YIK MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13vZ2lEPTB;ND65O|k1OiEQvF2= Mk\vV2FPT0WU
NCI-H1882 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTVwMEKwNFEh|ryP MoPTV2FPT0WU
MHH-CALL-2 NUHYZ2pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrMWVJpUUN3ME21MlA2ODR{IN88US=> MYPTRW5ITVJ?
U-87-MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7BTWM2OD13LkC5OFY3KM7:TR?= NXrwSZZjW0GQR1XS
NCI-H1092 NH2zVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv0TWM2OD13LkK2OVU2KM7:TR?= MYjTRW5ITVJ?
TE-441-T NVXaNldTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPncYRKSzVyPUWuNlc5OiEQvF2= NXz6[HZHW0GQR1XS
SK-MEL-1 NFv4RnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf5TWM2OD13LkK5NFQ1KM7:TR?= NWjBdIQzW0GQR1XS
EW-22 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f2TmlEPTB;NT6yPVQ3PiEQvF2= NXvYSlNCW0GQR1XS
MZ7-mel Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr1SGlKSzVyPUWuOFA3QTFizszN MWnTRW5ITVJ?
LP-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\BTWM2OD13LkSxNlkyKM7:TR?= MmjjV2FPT0WU
NCI-SNU-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jxRmlEPTB;NT62OFA4PCEQvF2= NWfRcZk2W0GQR1XS
LU-65 M4nLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPITWM2OD13Lke2N|c{KM7:TR?= MnzFV2FPT0WU
CW-2 NFjt[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHme4JqUUN3ME21Mlg2QTV7IN88US=> M2[zRXNCVkeHUh?=
WSU-NHL NGC4UG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHX[|ZXUUN3ME21Mlk2OTd2IN88US=> NEDWT3JUSU6JRWK=
IST-MES1 NUnJc49wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PBZWlEPTB;NT65OVQ1OyEQvF2= M4jRXnNCVkeHUh?=
U-266 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTi[YhKSzVyPUWuPVgzODJizszN NULhPVByW0GQR1XS
TALL-1 M{LiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PYeGlEPTB;Nj6xOFY5QCEQvF2= MlvGV2FPT0WU
Calu-6 M{n5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTBTWM2OD14LkG1N|E3KM7:TR?= NF\HWVdUSU6JRWK=
MMAC-SF M2qxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwMUi1OVYh|ryP MkHhV2FPT0WU
NCI-H82 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZwMkC0PFkh|ryP M4XvSXNCVkeHUh?=
RS4-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZwMkW4PVch|ryP NWfGWGVqW0GQR1XS
SNU-C2B NG\MRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DhXGlEPTB;Nj60NFk3QSEQvF2= M2npWnNCVkeHUh?=
BOKU MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7iV3VKSzVyPU[uOFc2QTdizszN MYLTRW5ITVJ?
C8166 NGizWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULoTFB3UUN3ME22MlU2QTF{IN88US=> MlKwV2FPT0WU
D-247MG M2DMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ZfmlEPTB;Nz6wOFM1PyEQvF2= MnznV2FPT0WU
EW-18 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfvTWM2OD15LkC3NlkzKM7:TR?= NHvxeY9USU6JRWK=
KG-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f6d2lEPTB;Nz62Nlc{QCEQvF2= NVH5VWFuW0GQR1XS
REH NUW4UldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT2dIdqUUN3ME23MlY5OTB7IN88US=> M4HrV3NCVkeHUh?=
U-698-M Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTdwOESzNVUh|ryP M1uw[nNCVkeHUh?=
KP-N-RT-BM-1 NHrQRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTdwOUOwNlkh|ryP NVTJXY0yW0GQR1XS
MS-1 M1jZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7UTWM2OD15Lkm2NFQyKM7:TR?= NEjaO5NUSU6JRWK=
SNU-C1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTdwOUixPVIh|ryP NGrxSo9USU6JRWK=
SK-MM-2 M4W5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2POfGlEPTB;OD6yOlA3PSEQvF2= M3nib3NCVkeHUh?=
LAN-6 M4fSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nyT2lEPTB;OD6zNFAxOSEQvF2= MXHTRW5ITVJ?
NEC8 NYnreWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzLTG81UUN3ME24MlMxPjlzIN88US=> NEDj[IdUSU6JRWK=
NCI-H1770 NFXO[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tNItKSzVyPUiuN|gxODJizszN MlfyV2FPT0WU
D-336MG NHzobmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vDZWlEPTB;OD60NFEyPiEQvF2= NXfQb2ZJW0GQR1XS
COLO-829 NHLncZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjdVFjUUN3ME24MlQ5QDd7IN88US=> M4DCN3NCVkeHUh?=
LS-513 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrj[|BVUUN3ME24MlU6PTl7IN88US=> NWjRSGliW0GQR1XS
YT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f2dWlEPTB;OD62NlQzPyEQvF2= NF\jdW5USU6JRWK=
EW-24 M{LLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O2RWlEPTB;OD63OlU1KM7:TR?= M4noT3NCVkeHUh?=
IST-SL1 NUf3Xm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3n[mRKSzVyPUiuPFY2PDNizszN NIrDNppUSU6JRWK=
CA46 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzye5VKSzVyPUiuPVUxQThizszN Mn;IV2FPT0WU
NCI-H1838 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfETWM2OD16Lkm4OlAzKM7:TR?= Ml;DV2FPT0WU
NCI-H719 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ubmlEPTB;OT6yOVI4QSEQvF2= M3PMVHNCVkeHUh?=
HCE-T MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDHZllVUUN3ME25MlMxQDVzIN88US=> NXHje2NtW0GQR1XS
A498 NXXjOJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nIZmlEPTB;OT6zOlEzPCEQvF2= MW\TRW5ITVJ?
LB831-BLC NWTDfm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXNRllDUUN3ME25Mlc3PTJzIN88US=> NX:4OFVEW0GQR1XS
SKM-1 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7QTWM2OD17Lki1PVY{KM7:TR?= NVHBZnAyW0GQR1XS
THP-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OwSmlEPTB;OT65OlkyQCEQvF2= M{n1RnNCVkeHUh?=
SHP-77 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjkcopzUUN3ME2xNE41ODdizszN MVHTRW5ITVJ?
EW-3 M{DqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT6Um1KSzVyPUGwMlYzQDlizszN NVXafJFuW0GQR1XS
KY821 Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xv[2lEPTB;MUCuO|Y{KM7:TR?= M1HzTnNCVkeHUh?=
NCI-SNU-1 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHITWM2OD1zMT6wNlE4KM7:TR?= Ml[0V2FPT0WU
HCC2218 M4j1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvoRZB2UUN3ME2xNU4{QTh4IN88US=> NFTOPHpUSU6JRWK=
IM-9 Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDCfmY{UUN3ME2xNU42OTB4IN88US=> NF\UXphUSU6JRWK=
NCI-H889 M1jsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nseGlEPTB;MUGuOVMyOyEQvF2= MnTPV2FPT0WU
HDLM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnLOHlJUUN3ME2xNk41OTV7IN88US=> MnXEV2FPT0WU
LB2518-MEL NXfHVGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Li[GlEPTB;MUKuOlgyPSEQvF2= MVXTRW5ITVJ?
NCI-H23 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HueGlEPTB;MUOuNlQzPSEQvF2= MULTRW5ITVJ?
NB17 M{DvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDifFB[UUN3ME2xN{41PTd7IN88US=> M3nOdHNCVkeHUh?=
NCI-H322M M2PMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrnXYpKSzVyPUG0MlQxPjhizszN NIOxboJUSU6JRWK=
SUP-T1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPtTWM2OD1zND60NVMh|ryP NUXmdFFxW0GQR1XS
ES3 NXT6VnVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj2bI5JUUN3ME2xOU4xPzB|IN88US=> Mlj4V2FPT0WU
ES5 NHqxbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrLTWM2OD1zNT6wO|g4KM7:TR?= MoHOV2FPT0WU
NCI-H1650 NU\mdYtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\1TWM2OD1zNT60PVc6KM7:TR?= M2HE[3NCVkeHUh?=
NCI-H226 NFrEc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq0TWM2OD1zNT64O|Y5KM7:TR?= NXXkfZdqW0GQR1XS
COR-L88 NVLYN3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDINpZKSzVyPUG2MlMyPCEQvF2= MYrTRW5ITVJ?
SCC-15 NXrOT2lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTEO5Z7UUN3ME2xOk4{QDZ7IN88US=> MYrTRW5ITVJ?
GOTO NUTKbHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF4LkS3PVMh|ryP MUDTRW5ITVJ?
SIMA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO2TWM2OD1zNj60PFAzKM7:TR?= NXjldoFqW0GQR1XS
NCI-H1299 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF5LkG1PVEh|ryP M1XGO3NCVkeHUh?=
NCI-H1581 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXsVHp2UUN3ME2xO{41OjF7IN88US=> NIL6SVdUSU6JRWK=
MHH-NB-11 M13BR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF5Lkm2PFMh|ryP NGP2T21USU6JRWK=
MFM-223 MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvtTWM2OD1zOD6wOVM5KM7:TR?= NVHvVpNPW0GQR1XS
ES7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF6LkW0N|Eh|ryP M3XQeHNCVkeHUh?=
JVM-3 M{jZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LGRmlEPTB;MUiuO|E4KM7:TR?= MoHWV2FPT0WU
RL M1zqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe3XJhKSzVyPUKwMlM5QCEQvF2= MWHTRW5ITVJ?
EC-GI-10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXXe|BKSzVyPUKxMlIxPDFizszN M2TBbHNCVkeHUh?=
LNCaP-Clone-FGC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJzLk[3Olgh|ryP NYDWZ3pNW0GQR1XS
IMR-5 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnHZlhKSzVyPUKxMlg1QTRizszN NYDDRmxNW0GQR1XS
KP-N-YS NYPD[Vc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jMOGlEPTB;MkGuPFc2KM7:TR?= NGS0SGNUSU6JRWK=
Mo-T MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jnNWlEPTB;MkKuNlE5PSEQvF2= NH7t[XhUSU6JRWK=
NCI-H128 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi4cHNKSzVyPUKzMlU5PTNizszN NF;iXnlUSU6JRWK=
RH-1 NH:2O|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH6T21YUUN3ME2yN{44QDZ4IN88US=> MlfRV2FPT0WU
NCI-H2171 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfXTGRKSzVyPUK0MlI1QDVizszN Mo\RV2FPT0WU
RPMI-8866 NEe2fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDQUmJKSzVyPUK2Mlc1OiEQvF2= Mnq3V2FPT0WU
SK-N-FI M2T1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TWZmlEPTB;MkeuN|gyOSEQvF2= M2\HPHNCVkeHUh?=
LOXIMVI NXXnWGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHWTWM2OD1{Nz64NFUyKM7:TR?= NIO2XJlUSU6JRWK=
P31-FUJ MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNzLkWzO|Qh|ryP NEHsZoFUSU6JRWK=
KMS-12-PE NWjRXYR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fiXGlEPTB;NEmuOVMxOiEQvF2= MWDTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

mTOR信号経路図

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID